Inductive 推出 Beacon-2，将药物属性转换为单次剂量估算
Inductive 的 Josh Haimson 和 Ben Birnbaum 正在与合作伙伴开展的实际项目中，将剂量模型与他们的新药物化学智能体 Indy 配对。
By RuntimeWire Staff · Published
Primary source: PR Newswire
为何重要
Beacon-2 将 Inductive 的能力从预测孤立的药物属性扩展到按具有临床意义的终点对化合物进行排序。其价值将取决于前瞻性证据，证明所建模的剂量估计能够改进实际的实验室和开发决策。
Josh Haimson, co-founder and CEO of Inductive, 于9月17日推出了 Beacon-2，为化学家和 AI 代理提供了一个系统，可以直接从小分子的化学结构估算其有效的人体剂量。
The product is the clearest expression yet of the bet Haimson and co-founder Ben Birnbaum have been building toward: drug discovery software becomes useful when it helps scientists make a consequential decision, rather than handing them another table of molecular properties to interpret.…
When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.